A Randomized, Double-Blind, Single-Dose, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of FL058 for Injection in Healthy Chinese Subjects.
Latest Information Update: 30 Sep 2021
At a glance
- Drugs FL 058 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Qilu Pharmaceutical
- 30 Sep 2021 New trial record